Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in China, with strong investor interest reflected in a subscription multiple of 4595.20 times during the IPO process [1][7]. Company Overview - North Chip Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board, emphasizing support for innovative high-end manufacturing enterprises with original technology [1][2]. - The company is recognized for its core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, which are the first domestically approved products in China [3][4]. Market Potential - The market for PCI (Percutaneous Coronary Intervention) procedures in China has surpassed one million annually, yet the penetration rate of IVUS and FFR products remains low, indicating significant growth potential [4][9]. - The company’s FFR system captured 30.6% of the domestic market share in its first year, while the IVUS system has reached approximately 1,000 hospitals since its launch in 2022 [4][5]. Financial Projections - North Chip Life projects revenue for 2025 to be between 520 million to 560 million yuan, representing a year-on-year increase of 64.24% to 76.88%, with net profit expected to reach 78 million to 88 million yuan, indicating a nearly threefold growth [1][10]. R&D and Innovation - The company has invested 389 million yuan in R&D from 2022 to 2024, with R&D expenses projected to account for 35.65% of revenue in 2024 [5][6]. - North Chip Life holds 185 domestic and international patents, with a strong focus on developing a comprehensive product line that includes 17 products across five categories [6]. Recognition and Achievements - The company has received multiple accolades, including recognition as a national "little giant" enterprise and awards for its innovative medical devices, further establishing its credibility in the market [6].
科创板迎“国产心血管智能化精准介入第一股” 北芯生命上市获关注